Health Care & Life Sciences » Biotechnology | Acceleron Pharma Inc.

Acceleron Pharma Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
113,163.00
176,460.00
104,847.00
139,690.00
277,227.00
291,312
Total Accounts Receivable
3,616.00
3,367.00
3,628.00
3,234.00
3,570.00
7,039
Other Current Assets
2,243.00
2,480.00
2,458.00
3,862.00
4,446.00
7,662
Total Current Assets
119,022.00
182,307.00
110,933.00
146,786.00
285,243.00
306,013
Net Property, Plant & Equipment
3,705.00
3,087.00
3,106.00
5,201.00
6,966.00
7,106
Total Investments and Advances
913.00
902.00
31,930.00
95,638.00
96,855.00
1,597
Other Assets
92.00
-
368.00
22.00
113.00
105
Total Assets
123,732.00
186,296.00
146,337.00
247,647.00
389,177.00
314,821
ST Debt & Current Portion LT Debt
16,868.00
-
-
-
-
Accounts Payable
885.00
724.00
875.00
1,590.00
1,086.00
Other Current Liabilities
9,457.00
8,529.00
13,616.00
14,559.00
15,659.00
Total Current Liabilities
27,210.00
9,253.00
14,491.00
16,149.00
16,745.00
Other Liabilities
38,710.00
20,758.00
5,396.00
5,901.00
7,215.00
Total Liabilities
65,920.00
30,011.00
19,887.00
22,050.00
23,960.00
Common Equity (Total)
57,812.00
156,285.00
109,263.00
225,597.00
365,217.00
Total Shareholders' Equity
57,812.00
156,285.00
109,263.00
225,597.00
365,217.00
Total Equity
57,812.00
156,285.00
109,263.00
225,597.00
365,217.00
Liabilities & Shareholders' Equity
123,732.00
186,296.00
146,337.00
247,647.00
389,177.00
Non-Equity Reserves
-
-
17,187.00
-
-

About Acceleron Pharma

View Profile
Address
128 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.acceleronpharma.com
Updated 07/08/2019
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L.